Clinical trials: Malignant Melanomas
Melanoma, Skin Cancer
The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors
In this study, we compared a negative pressure wound therapy, versus a conventional dressing in order to evaluate the most efficient wound therapy closure after axillary and inguinal lymph nodes dissections in the management of…
- Conditions
- Melanoma, Skin Cancer, Epidermoid Carcinoma, Neuroendocrine Carcinoma
- Trial name
- NCT04583605
- Testing
- PREVENA
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Metastatic Melanoma
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: Pembrolizumab (Keytruda) Trametinib (Mekinist) Dabrafenib (Tafinlar)
- Trial name
- NCT03149029
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Melanoma
Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)
This pilot study will examine facilitators and barriers that impact staff uptake for implementation of practice change involving ipsilateral IV insertion in patients with axillary lymphadenectomy/dissection in a single radiology…
- Conditions
- Breast Cancer, Melanoma, Thoracic Cancer, Lymphedema of Upper Arm
- Trial name
- iPIVAP (NCT04570722)
- Testing
- Ipsilateral peripheral IV insertion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Uveal Melanoma, Liver Metastases
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will develop in approximately 35%-50% of the patients within 10 years.
- Trial name
- SCANDIUM-III (NCT06519266)
- Testing
- PHP, IPI1/NIVO3, IPI3/NIVO1
- Where
- 6 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Vastra Gotaland Region
Melanoma
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease…
- Trial name
- CheckMate76K (NCT04099251)
- Testing
- Nivolumab
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 790 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma
This clinical pilot study will test the hypothesis that systemic low-dose IL-2 therapy significantly enhances the immunologic efficacy of a vaccine comprising melanoma peptides plus GM-CSF-in-adjuvant.
- Trial name
- MEL36 (NCT00928902)
- Testing
- low-dose IL-2, melanoma vaccine
- Volunteers
- 41 people
- Sponsor
- University of Virginia
Choroidal Melanoma, Indeterminate Lesions
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- NCT07421739
- Testing
- Non-interventional, digital, patient-reported, study
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Aura Biosciences
Melanoma
Does the Aid of MelaFind Affect Clinical Management Decisions
The objective of this study is to determine and compare the performance of dermatologists (in Germany) on the excision decision against the performance of MelaFind, a non-invasive and objective multi-spectral computer vision…
- Trial name
- NCT01387581
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Melanoma
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both IMP321/LAG-3 and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety and…
- Trial name
- LAG-3/IMP321 (NCT01308294)
- Testing
- 2 vaccine injections in 1 limb, 2 vaccine injections in distinct limbs, 2 "vaccine injections" in distinct limbs
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Advanced Unresectable Melanoma, Metastatic Melanoma
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy.
- Trial name
- NCT07237100
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kevin Kim, MD
Melanoma (Skin)
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other…
- Trial name
- NCT00976573
- Testing
- bevacizumab, carboplatin, everolimus
- Where
- 310 sites in United States
- Volunteers
- 149 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma (Skin)
S9804: Vinorelbine in Treating Patients With Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating patients who have stage IV…
- Trial name
- NCT00003828
- Testing
- vinorelbine
- Where
- 86 sites in United States
- Volunteers
- 24 people
- Sponsor
- SWOG Cancer Research Network
Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment.
- Conditions
- Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma
- Trial name
- INSPIRE (NCT02644369)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Melanoma, TOR Serine-Threonine Kinases
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
This is a single-armed, open-labeled and single-centered study of everolimus in selective patients with metastatic melanoma for evaluation of the efficacy and safety.
- Conditions
- Melanoma, TOR Serine-Threonine Kinases, Neoplasm Metastasis
- Trial name
- NCT01960829
- Testing
- Everolimus
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
- Trial name
- NCT04139902
- Testing
- Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination)
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Diwakar Davar
Melanoma (Skin), Non-melanomatous Skin Cancer
Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions
RATIONALE: New diagnostic procedures, such as bioelectric field imaging, may help find and diagnose melanoma and other skin cancers. It may also be a less invasive way to check for skin cancer.
- Trial name
- NCT00391300
- Testing
- bioelectric field imaging, biopsy, histopathologic examination
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Eastern Virginia Medical School
Melanoma, Non Small Cell Lung Cancer
Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors
Rationale: Tremendous anti-tumor effects have been achieved using immune checkpoint inhibitors for melanoma and NSCLC with long lasting responses of more than 2 years in a substantial subgroup of patients.
- Trial name
- NCT03946007
- Where
- Netherlands
- Volunteers
- 134 people
- Sponsor
- University Medical Center Groningen
Melanoma, Non Small Cell Lung Cancer
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
Background: The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- PragmaTIL (NCT06630611)
- Testing
- NMA-LD regimen, Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion, High dose IL-2
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Melanoma, Non-small Cell Lung Cancer
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial.
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT04609566
- Testing
- brentuximab vedotin, pembrolizumab
- Where
- 90 sites in United States
- Volunteers
- 161 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.